Proposed Topic (Most preferred): :
Research and Innovations (new projects / technology / innovations / service models)
Authors (including presenting author) :
Mr Vincent Kai Chung WONG(1), Mr. Howard Wong(1), Mr. William Chui(1), Ms Jiaxi LIN(2), Dr Celine SL CHUI(2, 3, 4)
Affiliation :
1. Department of Pharmacy, Queen Mary Hospital, Hospital Authority, Hong Kong
2. School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong
3. School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong
4. Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong
Introduction :
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. Existing risk prediction models may not fully apply locally since they were developed using multi-ethnicities cohorts without classification. In view of this, P-CARDIAC (Personalized CARdiovascular DIsease risk Assessment for Chinese), a machine learning-based cardiovascular risk prediction tool tailored for Chinese population, was developed and able to predict 10-year cardiovascular risk. It has also shown promise in pharmacy-led services, demonstrating its potential as an effective disease management tool beyond specialist outpatient clinics and into broader clinical settings.
Objectives :
For better facilitating P-CARDIAC in local clinical setting, a pilot study was conducted to investigate the feasibility of applying P-CARDIAC among Hong Kong population.
Methodology :
Patients who visited specialist out-patient clinic in Queen Mary Hospital from 1st September 2022 to 31st December 2023 will be recruited. Electronic health records (eHR) were accessed after seeking consent from patients. Health parameters from eHR were extracted for applying individuals’ initial prediction. Pharmacist-led consultation service from the collaboration with AKA and DHC/E (District Health Centre Express) were given to participants for providing health assessment service and promoting medication compliance with estimated score during the study period. Patients’ prospective of P-CARDIAC application and medication compliance questionnaires were conducted along with the service.
Result & Outcome :
The pilot study provided more clinical information with the application of the P-CARDAIC in practice and increased patients’ awareness of medication compliance.
Of 87.5% participants thought pharmacist-led consultation was helpful to lower their CVD risk during the follow-up and 62.5% participants thought P-CARDIAC was helpful for their health condition from our midterm progress summary. The pilot study helped to facilitate P-CARDIAC by using real-world data. It also demonstrated the feasibility of incorporating the risk prediction model in clinical setting for improving individual’s health management and better medication compliance.
